Back to top
more

Collegium Pharmaceutical, Inc. (COLL)

(Real Time Quote from BATS)

$12.09 USD

12.09
29,764

-0.42 (-3.36%)

Updated May 20, 2019 10:20 AM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
25.08%
18.07%
9.73%
5.25%
2.19%
10.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

C Value | A Growth | D Momentum | B VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for COLL

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Collegium Pharmaceutical, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Assets          
Cash & Equivalents 147 119 153 96 2
Receivables 78 10 2 0 0
Notes Receivable 0 0 0 0 0
Inventories 8 2 1 0 0
Other Current Assets 5 3 2 1 3
Total Current Assets 238 133 159 97 5
Net Property & Equipment 9 2 1 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 44 0 2 0 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 291 136 162 98 5
Liabilities & Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Notes Payable 0 0 0 0 5
Accounts Payable 12 6 9 4 2
Current Portion Long-Term Debt 2 1 3 3 1
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 175 24 9 2 2
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 5 0 0
Total Current Liabilities 189 31 26 8 10
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 10 0 1 4 7
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 200 31 27 13 17
Shareholders Equity 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Preferred Stock 0 0 0 0 77
Common Stock (Par) 0 0 0 0 0
Capital Surplus 429 402 358 214 12
Retained Earnings -337 -298 -223 -129 -102
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 92 104 135 85 -12
Total Liabilities & Shareholder's Equity 291 136 162 98 5
Total Common Equity 92 104 135 85 -89
Shares Outstanding 33.20 32.50 28.60 23.40 NA
Book Value Per Share 2.76 3.20 4.72 3.64 0.00

Fiscal Year End for Collegium Pharmaceutical, Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2019 12/31/2018 9/30/2018 6/30/2018 3/31/2018
Assets          
Cash & Equivalents 135 147 140 134 128
Receivables 85 78 67 68 66
Notes Receivable 0 0 0 0 0
Inventories 9 8 9 9 8
Other Current Assets 5 5 3 6 6
Total Current Assets 234 238 219 216 208
Net Property & Equipment 10 9 6 3 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 41 44 421 454 486
Deposits & Other Assets 10 0 0 0 1
Total Assets 294 291 647 673 696
Liabilities & Shareholders Equity 3/31/2019 12/31/2018 9/30/2018 6/30/2018 3/31/2018
Notes Payable 0 0 0 0 0
Accounts Payable 14 12 12 19 9
Current Portion Long-Term Debt 3 2 117 115 131
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 172 175 151 131 110
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 189 189 280 265 250
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 19 10 296 326 355
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 208 200 576 591 605
Shareholders Equity 3/31/2019 12/31/2018 9/30/2018 6/30/2018 3/31/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 433 429 417 412 407
Retained Earnings -347 -337 -346 -330 -317
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 86 92 71 83 91
Total Liabilities & Shareholder's Equity 294 291 647 673 696
Total Common Equity 86 92 71 83 91
Shares Outstanding 33.30 33.20 33.20 33.00 33.00
Book Value Per Share 2.59 2.76 2.13 2.51 2.75